ZENTALIS PHARMACEUTICALS INC (ZNTL)

These stocks are moving in today's after hours session

As the regular session of the US market concludes on Wednesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and...

Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm

/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Zentalis Pharmaceuticals, Inc....

Notable Monday Option Activity: ZNTL, JEF, SWKS

Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies

Company on track to present data from key clinical studies of azenosertib in the fourth quarter of 2024...

Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024

Azenosertib shows synergistic anti-tumor effects in combination with topoisomerase I (TOP1) inhibitor-based antibody drug conjugates...

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and...

Commit To Buy Zentalis Pharmaceuticals At $2.50, Earn 22% Annualized Using Options

Newman Ferrara LLP Announces Corporate Governance Investigation of Zentalis Pharmaceuticals, Inc. – ZNTL

Zentalis Pharmaceuticals, Inc. (ZNTL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

ZNTL Stock Earnings: Zentalis Pharma Misses EPS for Q2 2024

ZNTL stock results show that Zentalis Pharma missed analyst estimates for earnings per share the second quarter of 2024.

ZNTL Stock Earnings: Zentalis Pharma Misses EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Zentalis Pharma (NASDAQ:ZNTL) just reported results for the second quarter of 2...

Zentalis Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Progress

$426.4M cash, cash equivalents and marketable securities as of June 30, 2024;Projected cash runway into mid-2026 SAN DIEGO, Aug. 09, 2024...

ZNTL Investors Have Opportunity to Join Zentalis Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or the "Company") (NASDAQ: ZNTL)....

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and...

Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm

/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Zentalis Pharmaceuticals, Inc....

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or the "Company") (NASDAQ: ZNTL)....

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or the "Company") (NASDAQ: ZNTL)....

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or the "Company") (NASDAQ: ZNTL)....

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or the "Company") (NASDAQ: ZNTL)....

Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program

FDA has placed a partial clinical hold on ZN-c3-001, DENALI and TETON monotherapy studies of azenosertib Monotherapy data to be presented in the second...

RSI Alert: Zentalis Pharmaceuticals (ZNTL) Now Oversold

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK & SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company...

Zentalis Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

NEW YORK and SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company...

Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors

NEW YORK and SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company...

Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting

Administration of azenosertib combined with gemcitabine was well tolerated and resulted in clinically meaningful increase in event-free survival compared...

Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit

NEW YORK and SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company...

ZNTL Stock Earnings: Zentalis Pharma Beats EPS, Beats Revenue for Q1 2024

ZNTL stock results show that Zentalis Pharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress

Azenosertib clinical development plan on track with multiple data readouts in gynecological and other cancer types anticipated in the second half of 2024...